According to the official press news, Samsung collaborated with Bottneuro AG, a Swiss MedTech startup to improve the diagnosis and treatment of Alzheimer’s disease. Bottneuro AG has selected the Samsung Galaxy Tab S8+ 5G Enterprise Edition hardware to store and record therapy data in the Bottneuro Solution.
Powerful Therapy Through Galaxy Tab S8+ 5G Graphical Interface
Bottneuro AG’s technology identifies areas of the brain affected by the disease through 3D magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging data. Once identified, these regions can be targeted and electronically stimulated with Miamind neurostimulator technology. The Galaxy Tab S8+ 5G Enterprise Edition simplify handling the Bottneuro solution via a graphical interface.
“We were looking for a simple and reliable solution for our application. We found it with the Galaxy Tab S8+ 5G Enterprise Edition and Samsung is giving us great support in the development,” said Julius Klaas, CTO of Bottneuro AG.
Seamless Solutions
The Samsung Galaxy Tab S8+ 5G Enterprise Edition brings plenty of features and capabilities. It comes with a high-resolution Super AMOLED display providing brilliant clarity for both patients and healthcare providers and offers reliable long-lasting battery life.
“We are pleased to offer Bottneuro AG a reliable, safe and simple solution with Samsung Knox and to support their novel therapy approach,” added Daniele Casella, Head of MX B2B Mobile at Samsung Switzerland.
